World Journal of Endocrine Surgery

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 16 , ISSUE 1 ( January-April, 2024 ) > List of Articles

ORIGINAL RESEARCH

Behavior of Recurrences and Remissions According to Stages of the 7th and 8th Edition of the American Joint Committee on Cancer/Tumor Node Metastasis System in Thyroid Cancer Patients in a High-complexity Center, Cali, Colombia

Alin Abreu Lomba, Andres Delgado, Mónica Morales García, Reynaldo Calvajal, Rodrigo Cardenas, Juan Muñoz

Keywords : Recurrence, Thyroid cancer, Thyroid neoplasm, Tumor node metastasis staging system

Citation Information : Lomba AA, Delgado A, García MM, Calvajal R, Cardenas R, Muñoz J. Behavior of Recurrences and Remissions According to Stages of the 7th and 8th Edition of the American Joint Committee on Cancer/Tumor Node Metastasis System in Thyroid Cancer Patients in a High-complexity Center, Cali, Colombia. World J Endoc Surg 2024; 16 (1):15-19.

DOI: 10.5005/jp-journals-10002-1471

License: CC BY-NC 4.0

Published Online: 20-12-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Introduction: The 8th edition of the tumor node metastasis (TNM) system presents changes compared to the 7th edition. This study aimed to evaluate the behavior of recurrence and remission between stages of TNM 7th and 8th editions in a descriptive study of thyroid cancer. Materials and methods: Medical records of a level 4 clinic, thyroid cancer patients, over 18 years were reviewed. We restaged patients according to the TNM 8th edition; recurrence, remission, and excellent response (%) between TNM 7th and 8th editions were evaluated for concordance based on serum levels of thyroglobulin (Tg). Results: A total of 116 patients were evaluated. Of these, 84.5% (98/116) were women, with a mean age of 50.6 ± 16.5 at diagnosis. 92.2% (106/116) had papillary thyroid carcinoma. The mean radioactive iodine (RAI) activity was 63.4 ± 35.0 mCi. Using the TNM 8th edition, 82 patients (70.6%) were classified as stage I, 32 (27.5%) as stage II, 1 (0.9%) as stage III, and 1 (0.9%) as stage IV. After a median follow-up of 13.2 ± 2.8 months, 80.1% (93/116) maintained remission, 19.8% (23/116) had recurrence, and 43.9% (51/116) had an excellent response based on levels of Tg. The rates of remission, recurrence, and excellent response between TNM 7th and 8th editions were not statistically significant. Conclusions: About 72.4% of thyroid cancer patients were downstaged applying TNM 8th vs 7th edition. 100% of TNM 8th stage III–IV patients had a recurrence, and 100% of TNM 8th edition stage I and II patients had an excellent response.

PDF Share
  1. Cuenta de Alto Costo. Situación del cáncer en población adulta en el SGSSS de Colombia, 2019. Fondo. Colomb Enfermedades Alto Costo; 2019. pp. 1–336.
  2. American Cancer Society. Key Statistics for Thyroid Cancer. American Cancer Society; 2017. p. 1.
  3. Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol 2020;16:17–29. DOI: 10.1038/s41574-019-0263-x
  4. Zanoni DK, Patel SG, Shah JP. Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep 2019;21(6):52. DOI: 10.1007/s11912-019-0799-x
  5. Nixon IJ, Wang LY, Migliacci JC, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid 2016;26(3):373–380. DOI: 10.1089/thy.2015.0315
  6. Huang SH, O'Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol 2017;18(7):40. DOI: 10.1007/s11864-017-0484-y
  7. Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 2017;27(6):751–756. DOI: 10.1089/thy.2017.0102
  8. Kim TH, Kim YN, Kim HI, et al. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. Oral Oncol 2017;71:81–86. DOI: 10.1016/j.oraloncology.2017.06.004
  9. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016;388(10061):2783–2795. DOI: 10.1016/S0140-6736(16)30172-6
  10. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. DOI: 10.1089/thy.2015.0020
  11. Lamartina L, Grani G, Durante C, et al. Follow-up of differentiated thyroid cancer—what should (and what should not) be done. Nat Rev Endocrinol 2018;14(9):538–551. DOI: 10.1038/s41574-018-0068-3
  12. Evans C, Tennant S, Perros P. Serum thyroglobulin in the monitoring of differentiated thyroid cancer. Scand J Clin Lab Invest Suppl 2016;245:S119–S123. DOI: 10.1080/00365513.2016.1210339
  13. Chereau N, Oyekunle TO, Zambeli-Ljepović A, et al. Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system. Br J Surg 2019;106(7):889–897. DOI: 10.1002/bjs.11145
  14. Maggiore R, Perticone F, Mari G, et al. Impact of the 8th edition of the AJCC-TNM staging system on estimated cancer-specific survival in patients aged 45–54 years at diagnosis with differentiated thyroid carcinoma: a single center report. Int J Endocrinol 2021;2021:8820364. DOI: 10.1155/2021/8820364
  15. Nam SH, Bae MR, Roh JL, et al. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma. Oral Oncol 2018;87:158–164. DOI: 10.1016/j.oraloncology.2018.11.003
  16. Nava CF, Zanella AB, Scheffel RS, et al. Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort. Arch Endocrinol Metab 2019;63(1):5–11. DOI: 10.20945/2359-3997000000097
  17. Lee J-H, Youn S, Jung S, et al. A national database analysis for factors associated with thyroid cancer occurrence. Sci Rep 2020;10(1):17791. DOI: 10.1038/s41598-020-74546-3
  18. Underwood HJ, Patel KN. Comparing the 7th and 8th editions of the American Joint Committee on cancer staging systems for differentiated thyroid cancer: improvements observed and future horizons. Ann Surg Oncol 2019;26(9):2653–2654. DOI: 10.1245/s10434-019-07490-w
  19. Zanoni DK, Patel SG, Shah JP, et al. Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol 2019;18(6):52. DOI: 10.1007/s11912-019-0799-x
  20. Shah S, Boucai L. Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence. J Clin Endocrinol Metab 2018;103(2):689–697. DOI: 10.1210/jc.2017-02255
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.